Clinical Trial
A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001)
Investigator
Complete title:
A Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Anti-Tumor Activity of PF-07260437 in Advanced or Metastatic Solid Tumors
Trial phase:
Phase
Early Phase I
Study ID:
NCT05067972
Local study ID:
RG1121939
Summary:
A study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of PF-07260437, a B7-H4 x CD3 bispecific mAb, in participants aged =18 years of age with advanced or metastatic breast cancer, ovarian cancer or endometrial cancer. Adult participants with other advanced or metastatic high B7-H4 expressing tumors may be considered after discussion with and approval from sponsor.
Trial keywords:
Breast Cancer, Endometrial Cancer, Ovarian Cancer
Enrollment status:
Recruiting
Trial eligibility
** For Eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Other eligibility criteria may apply.
Learn more
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact us
For more information about Fred Hutch and to schedule an appointment.
